Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ORPN 1.5
Cash burn rate will be decreased sharply (already started) due to high revenues forecast upcoming earnings and beyond. these FDA approved drugs have $3.8m Market potential vs a few millions current Market cap.
it's newest FDA approval product Zolpimist, just been added a month ago hence will be represented in upcoming earning and beyond. see last Paragraph (above) includes market potential:
market potential:
strong Pipeline/ Catalysts:
2019 will be a huge year for this Company per both CEO and analysts. sales and revenues boost (yahoo Finance):
* Sales Growth 2019 by analyst coverage: 255.20%
* Revenue Estimate 2019 $13M
fits CEO's comments recently.
These block baster FDA approved drugs worth a lot more than a few millions market cap, that's for sure. Now can seat down and wait big data in a few weeks and a good chance it will be great like the previous one (and strong pipeline in 2019 too).
I expect a massive upside the coming weeks.
AYTU Finally we know the terms, Aytu BioScience (NASDAQ:AYTU) has filed a preliminary prospectus for a public offering of 839,695 shares of common stock and warrant to purchase up to the same number shares at a combined price of $2.62/share + warrant. sound better than expected (relating price and commons)
AYTU upcoming Catalysts/market potential: https://twitter.com/ash_trader/status/1044623102460727296
current MC under $5m! vs $3.6B Market space and products already started to hit the market!, can't find better reward than this one.
CEI took some profits, kept the rest. grabbed more aytu
CEI .70, called it yesterday at open at around .22
CEI .68 +80%
.48 Been following very closely past months. https://investorshub.advfn.com/boards/board.aspx?board_id=31670
.39 at close, .40 after hours.
thank you mottstocks, great DD, very informative, includes numbers
a bargain:
Sales Growth 2019 by analyst coverage:
255.20%
Revenue Estimate 2019 $13M
https://finance.yahoo.com/quote/AYTU/analysis?p=AYTU
fits CEO's comments recently. mentioned in my previous DD
AYTU see what's coming next earnings (at the bottom):
as mentioned before, always do DD by your own. reward could be something we I haven't seen for years of you ask me. defiantly worth 20-30 times current joke $4m Market cap (or about $6m fully diluted), not to mention another huge market potential (November P3 big data).
CEO: “if we only achieved 5% penetration in each of these markets, that would be approximately $90 to $100M net revenue. A rationally-valued specialty pharma comp would be valued at 3 to 5 times net revenue, so that would approximate a $300M to $500M”
CEI .29 +40%,
CEI .23, a great lotto at this point. if my DD is right, many will be surprised when earnings will be out. commodities & recent developments point of being a profitable these days. in this case it might be trading way above a buck. oil, crude...
SBOT $7.5 PT by Zacks: NCI SUPPLY CONTRACT: HIGHLIGHTS GROWING INTEREST OF KLH FOR CANCER IMMUNOTHERAPIES http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2018/SBOT-NCI-Supply-Contract-Highlights-Growing-Interest-of-KLH-for-Cancer-Immunotherapies-article/default.aspx
nano cap, most solid balance sheet the sector if not the entire NASDAQ market ( total assets/ total liabilities ratio Is 32!
total Assets almost been doubled $12.8m while total liabilities only 400k, net assets is $12.4m vs $7m Market cap. financed recently.
Nice activity on Friday's close.
Sure I did.and the previous one wasn't supposed to be the last one.it also mentioned here. If upcoming offering which already priced in, will be priced around $4/sh, when need arrives, it might brings a nice boost here. It was trading around $4.5/sh when company announced it 2 weeks ago..Then the race to Phase 3 results will be very interesting ( around November ).
it's a little short term dilution which is structured, for long term major upside. As I mentioned before, when such a low cap company w/ incredible market potential, blockbuster FDA approved pdoducts, plan to raise money when needs arrive, for solid reason, It usually skyrocket.
At $12-$15 /sh MC still under $50m ( fully diluted ). Already have FDA approval drugs and a good PHASE 3 data will no doubt could send it above $200m. CEO been talking about $300m-$500m on a conservative assumptions.
YTEN w/ such a low M. and solid Balance sheet (a Debt-free) this is a strong long term hold for me
https://twitter.com/PrayToBe/status/1043149196646391808?s=19
$ACAN 3.2 +10% Mentioned it. $AYTU keep holding this lotto for the long term. Used to be a $200m company, w/ FDA approval drugs. Big data later this year ( phase 3). Please check Phase 3 companies Valuation. company is trading 50% below cash on hand and will have more $8m cash when need arrives
Company products under the spotlight these days:
Tesla's Elon Musk works 120 hours a week, uses Ambien to sleep
https://t.co/RzIzNJCZlP ; ;
Drugmakers continue price increases: Aytu BioScience recently bought rights to a spray form of Ambien and then raised the price as much as 843% https://t.co/Dkn6PJQ2SS via @WSJ ;
" the biggest price increase this month -- of more than 700 percent --came from tiny Aytu BioScience Inc., for an obscure sleep drug called Zolpimist"https://t.co/sSM4gwBgBf ; ;
CEO ...
“if we only achieved 5% penetration in each of these markets, that would be approximately $90 to $100M net revenue. A rationally-valued specialty pharma comp would be valued at 3 to 5 times net revenue, so that would approximate a $300M to $500”
You welcome. Imagin a new stake will be announced pre Phase 3 data.... As I mentioned before ( see sticky post), meet my Risk /Reward requirements for a long term holding.
Good luck
Please check Phase 3 companies Valuation. company is trading 50% below cash on hand and will have more $8m cash when need arrives
Company products under the spotlight these days:
Tesla's Elon Musk works 120 hours a week, uses Ambien to sleep
https://t.co/RzIzNJCZlP ;
Drugmakers continue price increases: Aytu BioScience recently bought rights to a spray form of Ambien and then raised the price as much as 843% https://t.co/Dkn6PJQ2SS via @WSJ
" the biggest price increase this month -- of more than 700 percent --came from tiny Aytu BioScience Inc., for an obscure sleep drug called Zolpimist"https://t.co/sSM4gwBgBf ;
CEO ...
“if we only achieved 5% penetration in each of these markets, that would be approximately $90 to $100M net revenue. A rationally-valued specialty pharma comp would be valued at 3 to 5 times net revenue, so that would approximate a $300M to $500”
investors lost completely Confidence. Even a pink sheet company has more volume and interest. I'm very disappointing
very realistic for Block baster FDA approval.$aytu .. a lotto play (half serious) ... P3 data in November - if good, $aqxp all over again (from $1 to $55) ... check out the float and o/s after 1-20 reverse split this monday.
— 🌻kei 😸🦊🐺🐶 (@keitrader) August 16, 2018
YTEN Yield10 Bioscience Grants Research License to Forage Genetics to Evaluate Novel Yield Traits in Sorghum https://markets.businessinsider.com/news/stocks/yield10-bioscience-grants-research-license-to-forage-genetics-to-evaluate-novel-yield-traits-in-sorghum-1027554731
this stock might be trading at $50/sh in 2 years imo
CEO recently:
"Yield10 will ultimately achieve commercial success as a leading innovator in the Ag industry".
CEO knows what he is talking about. based on 2 analysts, In 2019 revenues will be increased by almost 20 times. Yahoo finance:
Revenue EstimateCurrent Qtr.(Sep 2018)Next Qtr. (Dec2018)Current Year(2018)Next Year(2019)No. of Analysts2 2 2 2Avg.
Estimate290k 310k 950k 4.98M
Keep an eye on SBOT higly undervalued. total Assets almost been doubled $12.8m while total liabilities only 400k, net assets is $12.4m vs $7m Market cap. financed recently.
" The only substantive competition today is biosyn but Stellar is the only KLH manufacturer that can rapidly and reliably ramp production" We continue to calculate fair value of SBOT at $5.50/share"..
which is equal to $38.5/ sh a/o today https://t.co/AaCe2OSzei
NIH just picked it...
Usually when I see the bears I'm buying more. Sound familiar ?
AYTU boom +55%
AYTU 4.22 + 40% hmmm
Sorry shorts.yoy should have listened .
AYTU 3.59 +19% Halted the way up...we warned shorts, bashers
ORPN 1.4 Unusual early volume.
Kei great alert. $MJ +50% SInce you have mentioned .the sector on fire. $TLRY Continues north too. $ACAN volumes surges yesterday probably because this Cannabis has a decent MC among low float Pot stocks and one of most solid balance sheet among them.
ORPN volume surges ( 3 times avg.), $4m MC, Phase 2b updates?
how exactly it works very good? https://tradingeconomics.com/united-states/balance-of-trade
U.S. trade deficit to worsen: experts http://www.xinhuanet.com/english/2018-09/18/c_137474996.htm
YTEN Here is how Crispr/Cas9 will change the world: